Table 1. Clinicopathologic Characteristics of 62 Patients who Underwent 66 Repeat Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy for Recurrent Peritoneal Carcinomatosis.
Characteristics | n=62 |
---|---|
Age, y | 46.4 ± 11 |
Sex | |
Male | 27(43.5%) |
Female | 35(56.5% |
ECOG status | |
0 | 23(37.7%) |
1 | 30(49.2%) |
2 | 5(8.2%) |
3 | 3(4.9%) |
BMI (kg/m2) | 27.8 ± 7.0 |
Primary tumor (n = 62), n (%) | |
Appendiceal | 33 (53.2) |
Colorectal | 4 (6.5) |
Mesothelioma | 7 (11.3) |
Ovarian | 8 (12.9) |
Gastric/GIST | 4 (6.5) |
Gallbladder | 1 (1.6) |
Sarcoma | 2 (3.2) |
Small bowel | 2 (3.2) |
Urachal | 1 (1.6) |
No. of CRS+ HIPEC | |
Two | 62 |
Three | 4 |
Resection status after first HIPEC, n (%) | |
R0-R1 | 27 (43.5) |
R2a | 25 (40.3) |
R2b-R2c | 10 (16.1) |
Resection status after second HIPEC, n (%) | |
R0-R1 | 27 (43.5) |
R2a | 16 (25.8) |
R2b-R2c | 19 (30.6) |
Peritoneal Carcinomatosis indexa | 9.2 ± 5.1 |
Adjuvant therapy after previous CRS+HIPEC, n (%) | 11 (17.7) |
Interval between previous CRS + HIPEC and diagnosis of recurrence, mo* | 27.0 +/- 29.0 |
Mean ± SD.
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy.